Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.59 USD | +4.47% | -11.02% | +66.81% |
Mar. 19 | North American Morning Briefing : Stock Futures -2- | DJ |
Mar. 14 | Larimar Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 464M |
---|---|---|---|---|---|
Net income 2024 * | -78M | Net income 2025 * | -140M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6
x | P/E ratio 2025 * |
-3.74
x | Employees | 42 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.66% |
Latest transcript on Larimar Therapeutics, Inc.
1 day | +0.90% | ||
1 week | -14.83% | ||
Current month | -36.83% | ||
1 month | -38.12% | ||
3 months | +54.25% | ||
6 months | +61.80% | ||
Current year | +59.67% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 65 | - | |
Michael Celano
DFI | Director of Finance/CFO | 65 | 20-05-27 |
Noreen Scherer
CTO | Chief Tech/Sci/R&D Officer | - | 18-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jonathan Leff
BRD | Director/Board Member | 55 | 20-05-27 |
Frank Thomas
BRD | Director/Board Member | 54 | 20-05-27 |
Jeffrey Sherman
BRD | Director/Board Member | 69 | 23-10-02 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 36 M€ | +4.74% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 7.59 | +4.47% | 514 809 |
24-03-27 | 7.265 | +0.90% | 442,161 |
24-03-26 | 7.2 | -5.01% | 522,207 |
24-03-25 | 7.58 | -6.30% | 514,406 |
24-03-22 | 8.09 | -5.49% | 781,587 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.67% | 464M | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.60% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |